Novel candidates for Parkinson¡¯s disease that have gathered the industry¡¯s attention are repeatedly failing to prove effectiveness in clinical trials. Bukwang Pharmaceutical was developing novel drugs for Parkinson¡¯s disease but failed to prove its efficacy in Europe phase 2 clinical trials.

D&D Pharmatech and Peptron also failed in phase 2 clinical trials. U.S. Amneal Pharmaceuticals and AbbVie also faced hurdles from the U.S. FDA. Despite of these circumstances, pharmaceutical companies continue to develop novel drugs for Parkinson¡¯s disease and work to turn around failing history.

According to industry sources on the 22nd, Denmark¡¯s Contera Pharma, Bukwang Pharmaceutical¡